CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer

CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer

Paola Zagami, MD, European Institute of Oncology IRCSS (IEO), Milan, Italy, comments on the potential for switching CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer, highlighting the importance of this approach in minimizing treatment interruptions due to adverse events. The FDA indication allows for long-term use of first-line treatment without frequent switches, and this approach is currently crucial for oncologists, as it can improve patient outcomes and quality of life. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

ภาพตัวอย่างวิดีโอ
CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
ภาพตัวอย่างวิดีโอ
Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors
ภาพตัวอย่างวิดีโอ
Dr. Accordino on the Utility of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
ภาพตัวอย่างวิดีโอ
Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer
ภาพตัวอย่างวิดีโอ
Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer
ภาพตัวอย่างวิดีโอ
CDK4/6 Inhibitors & Endocrine Therapy in Breast Cancer
ภาพตัวอย่างวิดีโอ
Evaluating predictors of benefit of CDK4/6 inhibition in breast cancer
ภาพตัวอย่างวิดีโอ
HR+ Breast Cancer: Differences Between CDK4/6 Inhibitors
ภาพตัวอย่างวิดีโอ
Breast Cancer Treatment Options 2025: CDK Inhibitors Guide
ภาพตัวอย่างวิดีโอ
Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer
ภาพตัวอย่างวิดีโอ
Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer
ภาพตัวอย่างวิดีโอ
CDK4/6 Inhibitors for HR+ Metastatic Breast Cancer
ภาพตัวอย่างวิดีโอ
CDK 4/6 inhibitors for older women with HR-positive breast cancer
ภาพตัวอย่างวิดีโอ
Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNA
ภาพตัวอย่างวิดีโอ
Module 2 - Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 Inhibitors
ภาพตัวอย่างวิดีโอ
Metastatic Hormone Receptor Positive (HR+) Breast Cancer Treatment Algorithm: Dr. Kevin Kalinsky
ภาพตัวอย่างวิดีโอ
Module 1 - Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 Inhibitors
ภาพตัวอย่างวิดีโอ
CDK4/6i in HR+ SABCS 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Sara Tolaney
ภาพตัวอย่างวิดีโอ
Treatment Following Relapse on CDK4/6 Inhibitors
ภาพตัวอย่างวิดีโอ
CDK4/6 Inhibitors & Endocrine Therapy: Selecting a Regimen